Stoke Therapeutics (NASDAQ:STOK) Posts Earnings Results, Misses Estimates By $0.13 EPS

Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings results on Monday. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13), FiscalAI reports. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The company had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million.

Here are the key takeaways from Stoke Therapeutics’ conference call:

• EMPEROR enrollment is complete with 162 patients enrolled in 10 months, no treatment discontinuations to date, and the phase III readout remains expected in the third quarter of 2027.
• Stoke reported supportive long-term open-label data for zorevunersen, including durable seizure reductions, statistically significant annual improvements in Vineland-3 cognition and behavior scores through four years, and no new safety findings after more than 930 doses.
• The company plans a rolling U.S. NDA beginning in the first quarter of 2027, supported by a pre-NDA FDA meeting later this year, and is advancing commercial preparations for a potential early-2028 launch. Stoke estimates approximately 16,000 U.S. Dravet patients, with about 6,000 patients under age 25 viewed as immediately addressable.
• Stoke ended the quarter with $354.3 million in cash and marketable securities and raised $65.7 million net through its ATM program, bringing pro forma cash to approximately $420 million and extending its expected runway through a potential U.S. launch.
• The pipeline is expanding, with STK-002 for ADOA moving into a higher-dose cohort and early safety and efficacy data expected in the first half of 2027; the company is also evaluating five preclinical SYNGAP1 candidates and hopes to select a development candidate in 2027.

Stoke Therapeutics Trading Up 2.4%

Shares of NASDAQ STOK traded up $0.70 during midday trading on Monday, hitting $29.56. 3,151,995 shares of the company’s stock were exchanged, compared to its average volume of 750,186. Stoke Therapeutics has a 12-month low of $12.71 and a 12-month high of $40.22. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -10.52 and a beta of 1.17. The business’s fifty day moving average price is $30.38 and its two-hundred day moving average price is $32.01.

Insider Buying and Selling

In related news, insider Barry Ticho sold 1,795 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the sale, the insider directly owned 34,826 shares of the company’s stock, valued at $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. The trade was a 7.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in STOK. AQR Capital Management LLC boosted its holdings in shares of Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after purchasing an additional 354 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics in the 4th quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after purchasing an additional 1,149 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in Stoke Therapeutics by 12.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after purchasing an additional 1,313 shares during the period. Finally, Swiss National Bank lifted its stake in Stoke Therapeutics by 2.2% in the fourth quarter. Swiss National Bank now owns 75,700 shares of the company’s stock worth $2,403,000 after purchasing an additional 1,600 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have commented on STOK. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, Weiss Ratings lowered shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.